Malarone Junior (Proguanil Hydrochloride, Atovaquone)

The combination works by two mechanisms: atovaquone blocks the mitochondrial electron transport chain of the malaria parasite, halting energy production, while proguanil is converted to cycloguanil, which inhibits the parasite’s dihydrofolate reductase enzyme, disrupting folate synthesis. Together they provide synergistic parasite clearance.

The dosing regimen for Malarone Junior is determined by the prescribing healthcare professional based on the patient’s age, weight, indication (prophylaxis or treatment), and local malaria resistance patterns. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Atovaquone/proguanil in pregnancy are limited, so the drug should be used only if the potential benefit justifies the potential risk. During breastfeeding, a risk‑benefit assessment should be performed by a qualified clinician, as the drug may be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Malarone Junior combines atovaquone and proguanil, offering a synergistic effect that reduces the chance of resistance compared with single‑agent therapies such as chloroquine. It is generally well‑tolerated and provides both prophylactic and therapeutic coverage, making it a preferred choice in many regions with chloroquine‑resistant malaria.

Malarone Junior should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Malarone Junior is taken orally with water, usually with food or a milky drink to improve absorption. The exact timing relative to meals and the duration of therapy depend on whether it is being used for prophylaxis or for treatment, as directed by the prescriber.

Serious risks, although rare, include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, significant liver enzyme elevations, hemolysis in patients with G6PD deficiency, and severe allergic reactions including anaphylaxis. Patients should seek immediate medical attention if they notice any of these symptoms.

Malarone Junior should be avoided in individuals with known hypersensitivity to atovaquone, proguanil, or any excipients in the formulation. Caution is also advised for patients with severe renal or hepatic impairment, and it is generally not recommended for pregnant women unless the benefits outweigh the risks.